“…Mr Gisserot said GSK’s vaccines business would be its strongest source of growth in coming years, highlighting the potential of its Cervarix jab to protect young women from cervical cancer…”
GSK are famous in China.. for all the wrong reasons…
That’s according to GSK’s new head of their China division (the replacement for the scandalous Mark Reilly ) – Hervé Gisserot..
I wonder when GSK will atone all the Seroxat damage that they caused to many thousands of us?…
I won’t hold my breath… considering one of Hervé’s drugs he aims to push on the Chinese is GSK’s Cervarix...
Cervarix is proving to be yet another controversial GSK drug but that won’t stop GSK and Hervé Gisserot pushing it in the new Chinese market will it?..
The side effects from Cervarix have been leaking out in the media since 2009, see the Telegraph for more:
Cervarix: the simple injection causing so much controversy
The cervical cancer jab Cervarix is currently under scrutiny after nearly 1,500 Britons have experienced adverse reactions to it.
Photo: RII SCHROER
Amanda Steele first noticed a change in her daughter Carly last summer. The normally exuberant 13-year-old had lost all of her energy. Whereas normally she would have spent her days outside on the trampoline, she now found it difficult to leave the sofa. It was even a struggle to walk unaided to the bathroom.
The blackouts, when they came, were more worrying. Mother would find daughter out cold on the floor of their Stockport home. Every joint in Carly’s body ached, and simple tasks such as washing her hair became impossible. Carly, on the brink of womanhood, suddenly seemed more like a toddler. It is six months now since she last attended school.
“It is like the light has gone out in her eyes,” says her mother. “It is absolutely heartbreaking to watch.”
At first, the doctors blamed vertigo. Then came a diagnosis of the balance disorder Labyrinthitis. Next, ME was suggested. Amanda is not convinced any of these conditions are implicated. What she believes is that Carly’s condition is related to the cervical cancer vaccine she received last year.
“The doctors all look at me like I am an idiot when I bring up the possibility of the jab having this effect on her, but she was a healthy, happy girl before she had it and now she isn’t, and I simply can’t believe that it has nothing to do with it.”
This week, relief of sorts arrived for the Steele family in the shape of a government report detailing the 1,340 instances of adverse reactions to the vaccine, Cervarix. Some girls have suffered paralysis, others convulsions; and some, like Carly, have experienced sight problems (in addition, Carly has now developed severe heat intolerance). Nausea, muscle weakness, fever, dizziness and numbness have also been reported.
Last updated: November 26, 2015 1:08 pm
GlaxoSmithKline has predicted a return to growth in China next year as it slowly begins to repair the damage from a corruption scandal which shattered the company’s reputation in one of the world’s most important pharmaceuticals markets.
In the most detailed account yet of its recovery efforts in China, GSK said it had rooted out the bribery that resulted in a record Rmb3bn ($488m) Chinese fine and halted the haemorrhaging of sales that has shrunk the business by more than a fifth.
Hervé Gisserot, GSK’s general manager in China, forecast renewed growth from this much-diminished base next year but said he had no desire to rekindle the breakneck expansion that led the company into crisis.
“We added a floor every year without making sure the building had the foundation to be sustainable,” he said. “My job now is to make sure the foundations are fit for future growth.”
Mr Gisserot admitted that GSK had become famous in China “for the wrong reasons” after being found guilty last year of what prosecutors described as “massive and systematic bribery” of doctors and health officials to boost prescriptions of its drugs.
But he promised to put the company at the forefront of efforts to clean up the Chinese pharmaceuticals market — behind only the US in size — after a radical overhaul of its sales and marketing model to reduce the risk of corruption.
The pharma model in China is not sustainable . . . others will have to adjust– Hervé Gisserot, GSK’s general manager in China
Measures include severing the link between sales and remuneration for GSK sales representatives, no longer paying doctors for speaking on the company’s behalf, and a ban on cash reimbursement for entertainment expenses.
Mr Gisserot warned that other companies risked punishment by Chinese authorities if they failed to follow GSK’s reforms. “I cannot believe GSK is a one off. This anti-corruption [drive] will continue. I hope others will learn before it is too late.”
GSK’s revenues in China fell 23 per cent between 2012 and 2013 and its sales force dropped from 5,000 to 3,000 as doctors shunned the company in the wake of the scandal. But the business has since stabilised and remains profitable.
After a modest upturn next year, Mr Gisserot predicted more “dynamic” growth from 2017 but said the days of double-digit annual expansion in the Chinese drugs market were over as the government tries to drive down prices. “The pharma model in China is not sustainable . . . others will have to adjust.”
Mr Gisserot said GSK’s vaccines business would be its strongest source of growth in coming years, highlighting the potential of its Cervarix jab to protect young women from cervical cancer.
China represented less than 3 per cent of GSK’s global sales last year at about £580m but is a strategically important part of the wider push by Sir Andrew Witty, chief executive, to tap rising demand for healthcare in the developing world.